hexenoyl cap is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
== History == President Dr. Arif Alvi granted approval for the reconstitution of the NEC on 8 June 2022, in accordance with the guidelines outlined in Article 156 of the Constitution. The NEC consists of a total of 13 members, led by the Prime Minister of Pakistan, who serves as the chairman. In addition to the chief ministers from all provinces, the council includes various federal ministers and nominated representatives from different political parties and provinces.
Chifles is the Spanish term used in Peru and Ecuador for fried green plantains sliced 1–2 mm (1⁄32–3⁄32 in) thick; it is also used to describe plantain chips which are sliced thinner. In Nicaragua, they are called "tajadas" and are sliced thinly the long way. They are commonly served alongside many dishes, including fritanga, and sold in bags by themselves. In Honduras, Venezuela and Central Colombia, fried ripened plantain slices are known as tajadas. They are customary in most typical meals, such as the Venezuelan pabellón criollo. The host or waiter may also offer them as barandas (guard rails), in common slang, as the long slices are typically placed on the sides of a full dish, and therefore look as such. Some variations include adding honey or sugar and frying the slices in butter, to obtain a golden caramel; the result has a sweeter taste and a characteristic pleasant smell. The same slices are known as amarillos and fritos maduros in Puerto Rico, Cuba, and the Dominican Republic respectively. In Panama, tajadas are eaten daily together with steamed rice, meat and beans, thus making up an essential part of the Panamanian diet, as with Honduras. By contrast, in Nicaragua, tajadas are fried unripened plantain slices, and are traditionally served at a fritanga, with fried pork or carne asada, or on their own on green banana leaves, either with a cabbage salad or fresh or fried cheese. In El Salvador, plátanos fritos are ripe plantain slices that are pan-fried and generally served as part of a traditional Salvadoran breakfast.
"Absinthe's second coming" Archived 2008-12-03 at the Wayback Machine – An April 2001 article in Cigar Aficionado about the first absinthe commercially produced in France since the 1915 ban. "Swiss face sobering future after legalizing absinthe" Archived 2016-12-02 at the Wayback Machine – A March 2005 Reuters article about the legalising of absinthe in Switzerland. "The Mystery of the Green Menace" – A November 2005 Wired magazine article about a New Orleans man who has researched the chemical content of absinthe and now distills it in France "The Return of the Green Faerie" – A wine and spirit journal article about the history, ritual, and artistic cult of absinthe The Wormwood Society Archived 2006-04-24 at the Wayback Machine – An independent organisation supporting changes to the US laws and regulations concerning absinthe. Provides articles, a forum and legal information. "What Is Absinthe" – Article discussing absinthe and its effect over mind and body. Absinthe in the online Culinary Heritage of Switzerland database.
Sources: en.wikipedia.org
The three substrates of this enzyme are loganin, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and oxygen. Its products are secologanin, oxidised NADP+, and water. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with oxygen as acceptor. The systematic name of this enzyme class is loganin:oxygen oxidoreductase (ring-cleaving). It is a member of the cytochrome P450 protein superfamily and participates in indole and ipecac alkaloid biosynthesis.
=== Archaeology in Neuchâtel during the 19th and 20th century === During the second half of the 19th century, many lake dwellings were found on the banks of lakes Neuchâtel, Bienne and Morat during a period dubbed "lake dwellings fever" (fièvre lacustre in french). The Jura waters correction lowered lake Neuchâtel height by 2.7 m which resulted in dozens of lake dwellings sites exiting from the waters. This made access to the artifacts far easier. Later, the construction of the A5 motorway (from Yverdon-les-Bains to Solothurn) alongside the north bank of Lake Neuchâtel led to the discovery of about 500'000 artifacts, many of them got included into the museum's collections.
=== Food sourcing === In 1999, while looking for ways to improve the taste of the carnitas, founder Steve Ells was prompted by an article written by Edward Behr to visit Concentrated Animal Feeding Operations (CAFOs). Ells found the CAFOs "horrific", and began sourcing from open-range pork suppliers. This caused an increase in both the price and the sales of the carnitas burritos. In 2001, Chipotle released a mission statement called Food With Integrity, which highlighted Chipotle's efforts to increase their use of naturally raised meat, organic produce, and dairy without added hormones. Ells testified before the United States Congress in support of the Preservation of Antibiotics for Medical Treatment Act, which was aimed to reduce the amount of antibiotics given to farm animals. From 2006 to 2012, the Coalition of Immokalee Workers (CIW), a Floridian farmworker organization, protested Chipotle's refusal to sign a Fair Food agreement, which would commit the restaurant chain to pay a penny-per-pound premium on its Florida tomatoes to boost tomato harvesters' wages, and to only buy Florida tomatoes from growers who comply with the Fair Food Code of Conduct. In 2009, the creators of the documentary film Food, Inc.
Sources: en.wikipedia.org
=== Estimates on how much is needed === The amount of YAN needed will depend on what the winemaker's goals are for fermentation, particularly whether or not wild fermentation is desired or if the wine will be fully fermented to dryness. The state of the grapes and the conditions of fermentation will influence the amount of nitrogen needed. Fruit that is damaged, moldy or botrytis infected will usually be more depleted of nitrogen (as well as other vitamin resources) when they come in from the vineyard than clean, intact grapes. This depletion can be further exacerbated by over clarification of the must and high sugar content. Wines fermented at higher temperatures tend to progress at a faster rate, requiring more nitrogen than longer, cooler fermentation. Also the amount of oxygen exposure will influence the rate of nitrogen uptake by the yeast with wine fermented in complete anaerobic conditions (such as many white wines in stainless steel tanks) requiring less nitrogen than wines fermented in barrels or open top fermentors. The suggested range given by enologists varies from 150 mg/L YAN to 400 mg of nitrogen per liter. Some studies have shown that maximum fermentation rates can be achieved with YAN in the 400 to 500 mg N/L range. However, not all winemakers will want to have a fermentation going at maximum rate (in terms of yeast biomass, temperature and speed) due to the impact that it can have on other sensory aspects of the wine such as aroma development and fruit retention.
=== Foundation: 1977 === On 2 March 1977, the General People's Congress adopted the "Declaration on the Establishment of the Authority of the People" at Gaddafi's behest. Dissolving the Libyan Arab Republic, it was replaced by the Great Socialist People's Libyan Arab Jamahiriya (Arabic: الجماهيرية العربية الليبية الشعبية الاشتراكية, al-Jamāhīrīyah al-‘Arabīyah al-Lībīyah ash-Sha‘bīyah al-Ishtirākīyah), a "state of the masses" conceptualized by Gaddafi. A new, all-green banner was adopted as the country's flag. Officially, the Jamahiriya was a direct democracy in which the people ruled themselves through the 187 Basic People's Congresses (BPCs), where all adult Libyans participated and voted on national decisions. These then sent members to the annual General People's Congress, which was broadcast live on television. In principle, the People's Congresses were Libya's highest authority, with major decisions proposed by government officials or with Gaddafi himself requiring the consent of the People's Congresses. Gaddafi became General Secretary of the GPC, although he stepped down from this position in early 1979 and appointed himself "Leader of the Revolution".
== History == AryoGen Pharmed is the first and largest mAb producer in MENA region with the vision of manufacturing high-quality biosimilar products for patients suffering from life-threatening diseases around the world and improving patient’s quality of life. AryoGen pharmed produces its own Active Pharmaceutical Ingredients (APIs) Using large-scale bioreactors according to cGMP guidelines, which have been approved by PIC/s members. Research and Development unit with laboratory-scale and pilot-scale production lines is equipped with cell culture equipment such as bioreactors and recombinant protein purification Facility. The state-of-the-art manufacturing sites of AryoGen have received major accreditation such as EU GMP European Medicines Agency (EMA). The quality of all products have been certified by the most reputable laboratories around the world. AryoGen Pharmed has several Tech-Transfer projects in different countries such as Turkey, Russia and Tunisia. In addition, the products of AryoGen Pharmed have been exported to different countries in Asia, Africa and Latin America.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.